US 11999753
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted A61PA61P35/00
Quick answer
US patent 11999753 (Tetrahydropyridopyrimidine pan-KRas inhibitors) held by Mirati Therapeutics, Inc. expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61P, A61P35/00